Summary:
- This article discusses a new neuropharmacological approach that has shown promise in reversing some of the core symptoms of autism spectrum disorder (ASD) in animal models.
- The researchers used a combination of two FDA-approved drugs, one that enhances the activity of a specific neurotransmitter receptor and another that inhibits the breakdown of that neurotransmitter, to target the underlying neurological mechanisms believed to contribute to ASD.
- The treatment was able to improve social interaction, communication, and repetitive behaviors in animal models, suggesting this approach could potentially lead to new therapeutic options for individuals with ASD, though further research is still needed to validate the findings and explore the long-term effects.